Jpmorgan Chase & CO Gritstone Bio, Inc. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Gritstone Bio, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 836 shares of GRTS stock, worth $25. This represents 0.0% of its overall portfolio holdings.

Number of Shares

836

Previous 35,368 97.64%

Holding current value

$25

Previous $90,000 100.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$0.62 - $2.35 $21,409 - $81,150	-34,532 Reduced 97.64%	836 $0
Q1 2024 May 10, 2024	SELL	$1.96 - $2.9 $54,499 - $80,637	-27,806 Reduced 44.01%	35,368 $90,000
Q4 2023 Feb 12, 2024	SELL	$1.28 - $2.85 $14,388 - $32,036	-11,241 Reduced 15.11%	63,174 $128,000
Q3 2023 Nov 14, 2023	BUY	$1.19 - $2.26 $3,912 - $7,430	3,288 Added 4.62%	74,415 $127,000
Q2 2023 Aug 11, 2023	BUY	$1.66 - $3.03 $59,678 - $108,931	35,951 Added 102.2%	71,127 $138,000
Q1 2023 May 11, 2023	BUY	$2.13 - $3.74 $11,193 - $19,653	5,255 Added 17.56%	35,176 $97,000
Q4 2022 Feb 13, 2023	BUY	$2.17 - $3.92 $54,549 - $98,540	25,138 Added 525.57%	29,921 $103,000
Q3 2022 Nov 14, 2022	BUY	$2.46 - $4.75 $4,905 - $9,471	1,994 Added 71.5%	4,783 $12,000
Q2 2022 Aug 11, 2022	SELL	$1.77 - $4.34 $112,131 - $274,943	-63,351 Reduced 95.78%	2,789 $7,000
Q1 2022 May 11, 2022	BUY	$4.03 - $12.19 $18,364 - $55,549	4,557 Added 7.4%	66,140 $273,000
Q4 2021 Feb 10, 2022	SELL	$8.76 - $13.71 $504,996 - $790,354	-57,648 Reduced 48.35%	61,583 $792,000
Q3 2021 Nov 12, 2021	BUY	$6.41 - $13.54 $764,270 - $1.61 Million	119,231 New	119,231 $1.29 Million

Others Institutions Holding GRTS

# of Institutions

Shares Held

37.5M

Call Options Held

1.46M

Put Options Held

168K

View Full List

About Gritstone bio, Inc.

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $2.19M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

More about GRTS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Gritstone Bio, Inc. Transaction History